Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves Outcomes in Pretreated Patients with Metastatic Cancer By Ogkologos - October 14, 2025 393 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROME study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities March 6, 2026 Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma September 6, 2022 Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC... June 30, 2023 “World’s Tiniest Baby” Has Been Released From The Hospital March 8, 2019 Load more HOT NEWS Trialling a new way to boost CAR T-cell therapy Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC... pCR Correlates with RFS and OS with Neoadjuvant Therapy in Stage... A Subset of Patients with NSCLC Respond Poorly to the COVID-19...
